Exelon (rivastigmine)

Presentation: Capsules containing 1.5 mg, 3.0 mg, 4.5 mg or 6.0mg rivastigmine (as the hydrogen tartrate salt).

Indication: Mild to moderately severe dementia of the A1zheimer type.

Dosage: 1.5 mg twice daily is the recommended starting dose. If well tolerated, it may be increased after a minimum of 2 weeks of treatment to 3 mg twice daily, subsequently to 4.5 mg twice daily, up to a maximum of 6 mg twice daily. Adverse effects may respond to omitting one or more doses. If they persist, the daily dose should be reduced to the previous well ­tolerated dose.

Contraindications: Known hypersensitivity to rivastigmine, other carbamate derivatives, or other ingredients of the capsules. Severe liver impairment since it has not been studied in this population.

Precautions/Warnings: As with other cholinomimetics, caution is recommended in patients with sick sinus syndrome, conduction defects (sino-atrial block, atrio-ventricular block), gastroduodenal ulcerative conditions in predisposed patients, history of or current respiratory disease, urinary obstruction, and seizures. The safety of Exelon is not established in pregnant and lactating women.

Interactions: Cholinomimetic drugs, anticholinergic medications, succinylcholine-type muscle relaxants during anaesthesia.

Adverse reactions: Nausea, vomiting, diarrhoea, abdominal pain, loss of appetite, dyspepsia, dizziness, headache. Rarely, angina pectoris, gastric and duodenal ulcers, gastrointestinal haemorrhage, bradycardia, seizures, rashes, and syncope.

Packs: Packs containing 28 or 56 capsules

Note: Before prescribing please read full prescribing information.

Novartis New Zealand Limited
Avondale, Auckland.
Phone: 09 8283149.

Date of Preparation: 25 July 2000
Reference Document Date: 30-Sep-1999 amended 24 March 2000

Further information